Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins – Source: Nature Medicine, online Oct 14, 2007

[First Paragraph] A molecular test for Alzheimer’s disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer’s and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer’s disease 2–6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer’s disease.

Source: Nature Medicine. Online Oct 14 2007. Published online: 14 October 2007 | DOI:10.1038/nm1653 by Ray S, Britschgi M, Herberr C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T. [E-mail: Tony Wyss-Coray, Stanford University School of Medicine,]

1 Star2 Stars3 Stars4 Stars5 Stars (106 votes, average: 3.00 out of 5)

Leave a Reply